Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > REGULATORY
REGULATORY
- LDP OKs FY2026 Budget Guidelines, Natural Increase Set at 400 Billion Yen
August 5, 2025
- PMDA Stresses Science-Based Decisions on Japanese PI Waivers: Symposium
August 5, 2025
- MHLW Trial Office Head Vows to Make Japan a Preferred Site for Clinical Studies
August 5, 2025
- MHLW Official Urges Use of New Fund to Drive Reorganization of Generic Sector
August 4, 2025
- MHLW Issues Guidance on Clinical Trial Design for Radiopharmaceuticals
August 4, 2025
- Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
- Japan Panel OKs Taisho’s Insomnia Med, 2 Other NMEs for Approval
August 1, 2025
- MHLW Selects 20 Organizations to Bolster Drug Discovery Clusters
August 1, 2025
- MHLW Orders Label Revisions for Semaglutide, Tirzepatide to Include Ileus Risk
July 31, 2025
- 23 Suspected Promotional Violations Identified for 18 Drugs in FY2024: MHLW
July 31, 2025
- MHLW Panel to Further Review Positioning of Susmed’s Insomnia App
July 31, 2025
- MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
- MHLW Raises Drug R&D, Supply Stability as FY2026 Budget Priorities
July 30, 2025
- OTC-Like Drugs Flagged as Key Agenda Item by CEFP Members
July 29, 2025
- Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Japan Panel Urges Consolidation of Cancer Surgery, Radiotherapy amid Shrinking Surgeon Workforce
July 29, 2025
- Two Oral Drugs Found to Exceed ADI for Red No. 3, MHLW Reports
July 28, 2025
- PMDA Launches Advisory Program for Academia, Startups Developing New Modalities
July 28, 2025
- MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
July 25, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…